Evidence-based Care and Therapeutic Updates to Reduce the Risk for Rapid Progression and Recurrence of Hepatic Encephalopathy

 

PROVIDER STATEMENT

This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc.

This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

DISCLOSURE OF COMMERCIAL SUPPORT

This educational activity is supported by an educational grant from Salix Pharmaceuticals.

PROGRAM OVERVIEW

Hepatic encephalopathy (HE) is a brain dysfunction caused by liver insufficiency and/or portosystemic shunting that manifests as
sub-neurological or psychiatric abnormalities that range in severity from subclinical alterations to coma. In the absence of effective treatment, HE is associated with a high risk of recurrence and hospitalization. Moreover, while significant advances in care have occurred over the past decade, patients hospitalized with HE continue to be at extremely high risk for mortality. Both the AASLD/EASL practice guidelines and ISHEN consensus statements provide detailed, evidence-based recommendations for the prevention of acute episode recurrence and strategies for improving the care of patients with HE. Join expert faculty Robert Rahimi, MD, MSCR as he discusses the latest data and best practices to align current clinical practice with these recommendations.

FACULTY

Robert Rahimi, MD, MSCR
Transplant Hepatology
Baylor University Medical Center
Associate Professor, Department of Medicine
Texas A&M Health Science Center, College of Medicine
Liver Consultants of Texas
Sammons Cancer Center
Dallas, Texas

Release date: December 22, 2022
Expiration date: December 22, 2023
Estimated time to complete activity: 60 minutes
TARGET AUDIENCE

This educational activity has been designed to meet the needs of hospitalists, general internists, subspecialists, and family practitioners caring for hospitalized patients.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Describe a plan of care for patients hospitalized with HE that is consistent with updated evidence-based recommendations
  • Review the efficacy and safety of therapies for treatment of acute episodes of overt HE and prevention of their recurrence
  • Identify crucial components of a transitional care plan to prevent future hospitalizations among patients with HE
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CE/CME credit for this activity. During the period of December 22, 2022 through December 22, 2023, participants must:

  • Read the learning objectives
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form
INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must complete the pretest, view the material, and complete the posttest and evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better. Pharmacists must check the CPE Monitor to access their credits within 60 days of the activity. Credit cannot be issued after 60 days.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CE/CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education

Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-22-239-H01-P.)

This is a knowledge-based activity.

FEE INFORMATION

There is no fee for completing this program.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

For information about ACPE or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. and Global Education Group adhere to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integrity Continuing Education, Inc. and Global Education Group are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by Integrity Continuing Education, Inc. and Global Education Group in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integrity Continuing Education, Inc. and Global Education Group to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE/CME activity:

Robert Rahimi, MD, MSCR
Consulting: Kaleido Biosciences Inc, Mallinckrodt Pharmaceuticals
Research Support: Axcella Health, Bausch Health, Mallinckrodt Pharmaceuticals

The planners and managers at Integrity Continuing Education, Inc. and Global Education Group have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest